

Atellica DCA Analyzer

Diabetes testing, evolved

siemens-healthineers.com/poc



SIEMENS
Healthineers

What if you could diagnose diabetes early and regularly monitor your patients?

More than 463 million people around the world have diabetes¹

Diabetes is one of the largest global-health emergencies of the 21st century. It continues to grow in prevalence but remains largely undetected.




50%
don't know it.¹

By 2045 it's projected that **700 million** people will have diabetes.¹



A 1% reduction in HbA1c may reduce amputation or death caused by blocked blood vessels by 43% and reduce instance of heart attack by 14%.²

Studies show that HbA1c levels reduce faster with point-of-care (POC) testing.³



University of Texas Medical Branch
Galveston, TX

Routine POC diabetes testing can improve patient outcomes and help meet KPIs

Siemens Healthineers solutions help providers achieve better results for clinics and patients.

High patient-satisfaction scores: 3.96 out of 4.0

Studies demonstrated flexible and improved patient workflows, which led to productive patient dialogue.

Improving care plans led to high patient-satisfaction scores: 3.96 out of 4.0.^{4,5}



Help improve patient glycemic control and identify early kidney disease

Studies have shown an overall reduction in A1c levels by as much as 35% for patients monitored with POC HbA1c testing vs. the lab.^{3,5}

POC albumin:creatinine ratio (ACR) testing identified 45% of patients with abnormal levels who needed immediate follow-up care.⁶





Proven to have a positive financial impact of \$24.65 per patient

In a study using POC HbA1c analyzers, testing was shown to lower operational costs by optimizing clinical operations and thereby reducing follow-up phone calls/letters and patient revisits.⁴



Help increase rate of early diagnoses

The use of a POC HbA1c test vs. standard practices greatly increases the likelihood of screening adults for diabetes.⁷



Atellica DCA Analyzer

Compact. Portable. Scalable. Customizable.

Building upon one of the industry's most trusted technologies for diabetes testing, the Atellica® DCA Analyzer puts fast, quality results right at your fingertips. Experience the performance and precision you need to improve outcomes, and get the speed, standardization, and personalization you want to boost efficiencies and meet growing demand.



Freedom

Freedom to optimize your workflows and evolve your POC experience

Scalable and connected

Connect and operate up to three test modules with a single display and transmit results with secure BLUETOOTH, wireless, or wired connections for seamless data transmission to LIS/HIS/EHR systems.


Scan cartridge QR code with the built-in 1D/2D bar-code reader

Flexible workflow


Link patient IDs and access results from wherever they are needed.

Compact and portable

The system's small footprint, light weight, and built-in handle enable easy movement for storage or bringing directly to patient.



Three easy steps




Results available in only 4 minutes!

Confidence

Gain confidence with results you can trust

Trusted performance

- Lab-quality results using technology with 30+ years of proven clinical reliability.
- Atellica DCA Analyzer strongly correlated to results from the Tosoh G8 laboratory method.⁸



- No clinically significant interferences from common hemoglobin variants for HbA1c measurements.⁹
- Atellica DCA HbA1c test is not affected by hemolyzed samples and can help reduce preanalytical errors.

Built-in safeguards



Auto-Checks[®] technology ensures accurate sample processing and reliable results, and built-in risk mitigation features provide an audit-ready solution.



Liquid ready controls help prevent pre-analytical errors.



Security measures protect patient data.

- No patient data transmitted between display and module.
- Operator access control prevents unauthorized access.
- Operator lockout after five failed attempts.
- TLS encryption protects from cybersecurity threats.
- USB debugging port is disabled.
- Manually exported data is password-protected.

Intuitive user interface

Simple operation and an intuitive UI decrease the likelihood of operator error, improve user experience, and reduce training complexity.



Better Patient Outcomes

Improve overall patient experience and outcomes



Rapid results

HbA1c results are available in only 4 minutes, ensuring timely patient consultation and treatment path.



Positive patient experience

Small sample size, sufficient sample hold time, and the ability to process hemolyzed samples mitigate pre-analytical errors and reduce patient discomfort from re-sticks.



Enhanced patient conversations

Built-in patient trend graphs complement patient consultations and aid in clinical decision making.



"POCT can significantly improve clinical operations with cost reductions through improved practice efficiency. The economic benefits of POCT may be realized in both fee-for-service and global payment environments."

J. Benjamin Crocker, MD

Medical Director, Ambulatory Practice of the Future
Massachusetts General Hospital, Boston, MA

"When we started, the hospital admission rate was between 20% and 30%. Now most clinics can get to around 10%, while we have rates of between 1% and 3%. That's a real benefit for patients and a big cost saver."

Dr. Henk Veeze

Pediatric Diabetologist and Co-founder
Diabeter Treatment Program, Rotterdam, Netherlands

A legacy of innovation and impact



30_{yrs}

of trusted immunoassay
technology



600+

peer-reviewed articles
and clinical citations

NGSP- and IFCC-certified annually

At Siemens Healthineers, our purpose is to enable healthcare providers to increase value by empowering them on their journey toward expanding precision medicine, transforming care delivery, and improving patient experience, all made possible by digitalizing healthcare.

An estimated 5 million patients globally benefit every day from our innovative technologies and services in the areas of diagnostic and therapeutic imaging, laboratory diagnostics, and molecular medicine, as well as digital health and enterprise services.

We are a leading medical technology company with over 120 years of experience and 18,000 patents globally. Through the dedication of more than 50,000 colleagues in 75 countries, we will continue to innovate and shape the future of healthcare.

Atellica, Auto-Checks, DCA, and all associated marks are trademarks of Siemens Healthcare Diagnostics Inc., or its affiliates. All other trademarks and brands are the property of their respective owners.

Product availability may vary from country to country and is subject to varying regulatory requirements. Please contact your local representative for availability.

References:

1. International Diabetes Federation. IDF diabetes atlas. 9th edition. Available from: <http://www.diabetesatlas.org/>.
2. Stratton, et al. BMJ. 2000;21:405-12.
3. Petersen J, et al. Effect of point-of-care on maintenance of glycemic control as measured by A1c. Diabetes Care. 2007 Mar;30(3).
4. Crocker, et al. Patient satisfaction with point-of-care laboratory testing: report of a quality improvement program in an ambulatory practice of an academic medical center. Clinica Chimica Acta. 2013;424:8-11.
5. Schnell, et al. Impact of HbA1c testing at point of care on diabetes management. Journal of Diabetes Science and Technology. 2017;11(3):611-17.
6. Murtuza MM, et al. POD2ER: Prevention and Organization against Diabetes Dialysis with Education and Resources. Kidney Dis. 55:181-91.
7. www.annfammed.org/content/15/2/162.full.pdf.
8. Siemens Healthcare Diagnostics Inc. Internal study conducted at Western Michigan University School of Medicine. 2019.
9. <http://www.ngsp.org/interf.asp>.

Siemens Healthineers Headquarters

Siemens Healthcare GmbH
Henkestr. 127
91052 Erlangen, Germany
Phone: +49 9131 84-0
siemens-healthineers.com

Published by

Siemens Healthcare Diagnostics Inc.
Point of Care Diagnostics
2 Edgewater Drive
Norwood, MA 02062-4637
USA
Phone: +1 781-269-3000